Fresenius and WuXi Biologics agree development partnership covering up to 37 biosimilar candidates
Fresenius has entered an exclusive development agreement with WuXi Biologics covering options for up to 37 biosimilar candidates, potentially more than doubling its combined marketed and pipeline portfolio.
The agreement, announced on 2 November 2026, allows Fresenius to select biosimilar development programmes over the next decade while retaining exclusive global commercialisation rights and compensating WuXi Biologics through a fee-for-service development structure.
Initial targets include biosimilars referencing polatuzumab vedotin and teprotumumab, with the originator products across the potential portfolio representing more than €370 billion in aggregate sales rather than a disclosed transaction value.
Field | Content |
Article Type | Deals |
Company | Fresenius |
Partner | WuXi Biologics |
Deal Type | Exclusive biosimilar development agreement |
Announcement Date | 2 November 2026 |
Agreement Duration | Up to 10 years for candidate selection |
Maximum Potential Biosimilar Candidates | 37 |
Existing Marketed and Pipeline Portfolio | 29 molecules |
Potential Expanded Portfolio | 66 molecules |
Development Structure | Fresenius may select individual biosimilar development programmes |
Partner Responsibilities | WuXi Biologics provides development services for selected programmes |
Commercialisation Rights | Fresenius retains exclusive global commercialisation rights |
Payment Structure | Fee-for-service development payments |
Financial Consideration | Not quantified in supplied summary |
Referenced Originator Product Sales | More than €370 billion in aggregate sales |
Originator Sales Clarification | Aggregate originator product sales are not the agreement's financial value |
Initial Reference Product | Polatuzumab vedotin |
Additional Reference Product | Teprotumumab |
Product Category | Biosimilars |
Therapeutic Areas | Potential oncology and other specialty biologic indications |
Geographic Scope | Global commercialisation rights |
Regulatory Status | No new biosimilar approvals announced |
Transaction Distinction | Options covering up to 37 development candidates; not 37 completed acquisitions or approved products |
What Happened | Fresenius and WuXi Biologics agreed an exclusive development framework covering up to 37 potential biosimilar candidates. |
Why It Matters | The agreement could substantially expand Fresenius' biosimilar portfolio and strengthen its long-term position in global biologics competition. |
Strategic Rationale | Use external development capabilities to accelerate biosimilar pipeline expansion while retaining worldwide commercialisation rights. |
Key Takeaway | Fresenius has secured options to develop up to 37 biosimilars, with programme-specific payments and no disclosed aggregate deal value. |
What to Watch | Candidate selection, development timelines, regulatory submissions, manufacturing arrangements and future biosimilar launches. |
Primary Source | Fresenius |
Primary Source URL | https://www.fresenius.com/node/7451 |
Relevant Date | 2 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare